AstraZeneca 6-K 2015
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month o July 2015
Commission File Number: 001-11960
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca Half Year Results 2015>
Tomorrow, Thursday, 30 July 2015, AstraZeneca will release half year results for 2015 at 07:00 bst.
An analyst presentation of the half year results will take place at 12:00 bst and will be accessible by a choice of two routes:
The presentation will be available to download on the AstraZeneca Investor Relations website http://www.astrazeneca.com/investors 15 minutes before the analyst presentation begins.
Teleconference with Q&A>. Dial in numbers:
UK (freephone): 0800 694 2370
International: +44 (0) 1452 557 749
Sweden (freephone): 0200 883 079
US (freephone): 1 866 977 7645
Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website http://www.astrazeneca.com/investors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.